Novartis Issues $120M Drug Recall, Plant Suspension

Law360, New York (January 9, 2012, 2:08 PM EST) -- Novartis Consumer Health Inc. recalled several popular over-the-counter drugs and suspended operations at a Nebraska facility Sunday following consumer complaints about damaged pills, inconsistent packaging and mixed tablets, taking a $120 million charge to do so.

The drugmaker said it was voluntarily pulling certain lots of Excedrin, NoDoz, Bufferin and Gas-X Prevention over concerns that they may contain broken or chipped pills, or stray tablets or capsules from different Novartis products.

An estimated $120 million charge in the fourth quarter of 2011 will cover the recall...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.